Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RTY-694
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rectify Announces RTY-694 Modulator for Primary Sclerosing Cholangitis Candidate
Details : RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow, being developed for primary sclerosing cholangitis (PSC).
Product Name : RTY-694
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 22, 2024
Lead Product(s) : RTY-694
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
Details : ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 14, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
Reset All
